A drug called sorafenib stopped progression of desmoid tumors for 80 percent of patients taking the drug over a time of two years as a part of phase 3 trial. Desmoid tumors which is well known as aggressive fibromatosis. They grow abnormally in the connective tissue and has a capability of impacting anywhere in ...